AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Hengrui Medicine's First Half Profit Rises 30%
ByAinvest
Wednesday, Aug 20, 2025 10:23 am ET1min read
Jiangsu Hengrui Medicine Co. reported a 30% jump in H1 profit, driven by strong sales of anti-tumor drugs, anesthetics, contrast agents, anti-inflammatory drugs, and cardiovascular disease treatments. The company's growth was fueled by its diversified product portfolio and expanding market share in the Chinese pharmaceutical industry.
Jiangsu Hengrui Medicine Co., one of China's largest pharmaceutical companies, reported a significant 30% increase in its first-half profit, driven by robust sales of its anti-tumor drugs, anesthetics, contrast agents, anti-inflammatory drugs, and cardiovascular disease treatments. The company's diversified product portfolio and expanding market share in the Chinese pharmaceutical industry contributed to its strong financial performance.According to analysts' consensus estimates from Bloomberg, Hengrui's net profit for the first half of 2025 rose 40% year-over-year (YoY) to 4.1 billion yuan (US$570.8 million), with revenue up 9% to 15.7 billion yuan [1]. This growth was largely attributed to the successful rollout of novel drugs and revenue from technology licensing. The company's focus on innovative drug development has reduced its reliance on less lucrative generics, a trend that is expected to continue.
Generics accounted for 43% of Hengrui's revenue in 2024, down from 62% in 2022, and this figure is projected to fall to 23% by 2027 [1]. This shift in revenue structure is a key driver of the company's profit growth, as it moves away from the lower-margin generics market towards higher-margin innovative drugs.
Hengrui's success in the first half of 2025 underscores the impact of a decade of policy reforms in China that have raised the quality of generics and streamlined the approval process for innovative drugs. These reforms have encouraged pharmaceutical firms to invest in novel drug development, enhancing the industry's global competitiveness.
References:
[1] https://www.scmp.com/business/article/3322005/chinese-pharma-firms-hengrui-hansoh-expected-post-strong-first-half-profits?module=china_future_tech&pgtype=homepage
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet